Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-3501 in Advanced CLDN18.2+ Gastric, Gastroesophageal Junction, and Pancreatic Cancer
NCT07481357Phase 1Recruiting
- Sponsor
- Dong-A ST
- Start
- May 2026
- Primary completion
- Feb 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of DA-3501 in gastric cancer (GC), gastroesophageal junction cancer and pancreatic ductal adenocarcinoma (PDAC) (11 arms), sponsored by Dong-A ST. Primary endpoints: Maximum Tolerated Dose at 21 days and Optimal Biological Effective Dose at 42 days. Started May 2026; status: recruiting.
02
Drugs
DA-3501
03
Conditions
gastric cancer (GC)gastroesophageal junction cancerpancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07481357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07481357.